31
Jan
2008
I’m Only a Bill: That Is HB08-1001
Posted in My Rants
With an invitation from the Colorado Bioscience Association I packed my things and headed over to the State Capital to listen in on the Colorado House Finance Committee deliberate over House Bill 08-1001. It is an incredible journey a that bill must follow in order to become law; happily HB1001 shall continue on its voyage, [...]
30
Jan
2008
A very interesting few days for Pharmion (NASDAQ: PHRM) and Celgene (NASDAQ: CELG) and how they are faring in their product approval efforts in Europe. The European Medicines Agency issued a positive opinion to recommend approval of Pharmion’s Thalidomide® for use in combination with melphalan and prednisone as first line treatment for patients with untreated [...]
29
Jan
2008
***1/30 POST UPDATE*** Here is a link to the letter from the FDA, click (here) to read. There is not really too much to go on here, but …an FDA warning letter was recently issued relative to the antibiotic faropenem and the company filed an 8K with the SEC yesterday. “On January 22, 2008, Replidyne, [...]
28
Jan
2008
Do You Speak FBBp?
Posted in FBBp
Fitzsimons BioBusiness Partners (FBBp) is the premier business development organization serving the Colorado bioscience community. The Mission of FBBp is: To nurture and grow viable and sustainable bioscience businesses in order to establish a global position for the bioscience industry in Colorado, with its epicenter at the Colorado Science + Technology Park @ Fitzsimons. The [...]
25
Jan
2008
Invention to Venture the workshop in technology entrepreneurship national tour pulls into Denver on 13 March. The day long seminar (8:00am – 4:00pm) is tailored for students, post-docs and researchers. Sounds like the business schools in CO may want to bring this to the aspiring MBA’s as well. Invention to Venture provides an overview of [...]
22
Jan
2008
22
Jan
2008
Don’t miss what promises to be a most informative Colorado Bioscience Association BioBreakfast (7:30 – 9:00am tomorrow 23 January) with CU’s new Vice Chancellor for Research, Dr. Richard Traystman. Dr. Traystman will be joined by Ronald J. Sokol, MD Professor and Vice Chair of Pediatrics and together they will provide an overview of how companies [...]
21
Jan
2008
Isogenis is focused upon novel immune modulating therapeutics for the treatment of immune disorders, genetic diseases, and transplant tolerance. A number of animal veto effect exploitation model transplantation systems have been developed for: pancreatic islet, liver, and heart transplantations, and have subsequently validated that their approaches have permanently protected tissues from rejection. Current foci of [...]
18
Jan
2008
18
Jan
2008
It was back in 2005 when Lohocla Research Corp was featured on CLSDF. Progress continues to made and thus the update. A quick background… Lohocla is a development-stage company focused on the therapy and diagnosis of pain, psychiatric, and addictive disorders. Products include rationally designed therapeutics and diagnostic tools developed for mental health and nervous [...]
17
Jan
2008
If you are ready to see some extraordinary next generation medical device technology then be certain to make it down to tomorrow’s Tensegrity Prosthetics Investor Demo Day. Founder and technology architect Jerome Rifkin will be on hand to direct the demo and address all inquires from engineering to capital sourcing. With an excitingly demonstrable experience, [...]
16
Jan
2008
Perhaps not squarely on certain peoples radars in these parts OSI Pharmaceuticals (NASDAQ: OSIP) is sometimes not uttered in the same breath by some when referring to public CO companies, easy to do I suppose since corporate headquarters are actually located in Melville, NY however, a very significant campus is here in Boulder, housing both [...]
15
Jan
2008
CU TTO: The Stars Come Out at Night
Posted in My Rants
It was a who’s who on the red carpet for last nights 6th Annual University of Colorado Technology Transfer Awards dinner. The evening kicked off with a talk by Governor Bill Ritter who unambiguously understands and supports the value that the process of technology transfer plays in intellectual capital commercialization effort yielding state wide economic [...]
Life Science Deal Flow PARTNERS
-
